CDE Special Approval Varieties

This resource is a public listing mAIntained through China's Center for Drug evaluation (CDE), a division of the National Medical Products Administration. It compiles drug varieties that have entered special review or APProval pathways, giving industry observers a way to see which products are being fast-tracked through the regulatory process. Because it is an official government page rather than a commercial AI product, it functions as a reference dataset for Professionals who need to track phArmaceutical review ACTivity in China.

What it does

The page presents a structured list of special approval varieties. Each entry typically IDEntifies a drug or application that has been assigned to a priority, conditional, or otherwise expedited review route. Visitors can browse the list to underStand the scope of products receiving special attention from regulators. The Information is published for transparency and is intended to support regulatory affairs work, market research, and Competitive Analysis.

Key capabilities

• Displays a catalog of drug varieties handled under special approval procedures.
• Offers a publicly accessible window into CDE review activity.
• Serves as a starting point for deeper regulatory research when cross-referenced with other CDE publications.
• Supports tracking of which therapeutic areas or sponsors appear in accelerated pathways.

Who it is for

The listing is most relevant to regulatory affairs specialists, pharmaceutical researchers, market intelligence analysts, investors following China's drug pipeline, and consultants advising on approvals. Journalists and policy researchers may also consult it when reporting on drug review trends. It assumes a reader already familiar with Chinese regulatory terminology and the distinction between standard and special review routes.

How to get started

Access the page through a standard web browser. There is no account requirement for viewing the public list. Users should be prepared for a Chinese-language interface and should confirm the current scope and update cadence directly on the site, since publishing schedules and field DeFinitions may vary. For rigorous analysis, pair the list with official CDE announcements and guidance documents rather than relying on the list alone.

Pricing and access caveat

Viewing the page is free and does not require payment. However, the site is operated for a domestic Chinese audience, so availability from outside the region may vary, and loading speed or accessibility could be inconsistent. No English translation is guaranteed. Details such as the exact review categories, update frequency, and download options may change without notice, so verify any figures against primary CDE sources before citing them in fORMal work.